Clinical Trial Update: A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1/1B study of ST-01156, a small-molecule RBM39 degrader, in patients with advanced solid tumors. Recruitment is ong…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Ewing Sarcoma
• Hepatocellular Carcinoma
• Solid Tumors

Drugs mentioned

• ST-01156

Snippet

Sponsor: SEED Therapeutics, Inc. | Conditions: Advanced Solid Tumors, Ewing Sarcoma | Phase 1 | Status: RECRUITING